GlassScriptPhysician profile
Tara M Harmonosky
NPI 1588086763
$5,067.89
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $949 · 2022: $1,361 · 2023: $1,680 · 2024: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.79 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,698.85 | 2021-2024 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $683.61 | 2021-2024 | |
| Amgen INC. | $319.30 | 2021-2024 | Tavneos, Parsabiv |
| Glaxosmithkline, LLC. | $264.65 | 2022-2024 | Benlysta, Jesduvroq |
| Daiichi Sankyo INC. | $236.50 | 2021-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $226.15 | 2021-2024 | Farxiga, Evusheld, Lokelma |
| Calliditas Therapeutics US INC. | $155.69 | 2022-2024 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.55 | 2023-2024 | Jardiance |
| Akebia Therapeutics INC | $155.51 | 2021-2024 | Auryxia, Vafseo |
| Nxstage Medical, INC. | $120.34 | 2023 | Nxstage System One |
| Travere Therapeutics, INC. | $117.94 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $104.91 | 2021-2023 | Terlivaz |
| Opko Pharmaceuticals, LLC | $101.09 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $99.55 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $87.12 | 2021-2023 | Ultomiris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $84.60 | 2022-2024 | Jynarque |
| Lilly USA, LLC | $63.74 | 2024 | Jardiance |
| Kyowa Kirin, INC. | $61.65 | 2023-2024 | Crysvita |
| Ardelyx, INC. | $54.06 | 2023-2024 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $51.84 | 2022-2023 | |
| Bard Peripheral Vascular, INC. | $40.15 | 2024 | Lutonix Drug Coated Balloon |
| Novartis Pharmaceuticals Corporation | $38.06 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $35.53 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $35.19 | 2021 | |
| Medtronic, INC. | $31.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.83 | 2023 | Gattex |
| Pfizer INC. | $19.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Harmonosky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.